Infectious disease cases up 54.5% in South Korea
South Korea saw a 54.5 percent rise in non-COVID notifiable infectious disease cases in 2024 compared to the previous year, driven largely by a surge in respiratory illnesses among children, according to a new report from the Korea Disease Control and Prevention Agency on Thursday.
The 2024 annual report on infectious disease, based on data from the newly launched integrated control information system, found that 168,586 cases of first to third-tier notifiable diseases — excluding COVID-19 and syphilis, which both had changes in their tiers — were reported last year, up from 109,087 in 2023.
Pertussis, otherwise known as whooping cough, accounted for much of the increase, with cases jumping from just 292 in 2023 to 48,048, over a 164-fold increase, in 2024. Scarlet fever and chickenpox also surged, with 6,642 and 31,892 cases reported, respectively. Carbapenem-resistant Enterobacteriaceae, a dangerous antibiotic-resistant infection, reached 42,347 cases.
Despite the overall increase in these illnesses, the total number of reported cases of all monitored infectious diseases plummeted by 97 percent from 2023, largely due to the reclassification of COVID-19 as a lower-tier disease.
The number of deaths from notifiable diseases, excluding tuberculosis, rose 18.2 percent to 1,238 in 2024. CRE infections were the leading cause of death among these, with 838 fatalities.
KDCA Commissioner Jee Young-mee emphasized the importance of early reporting by medical institutions.
"Reporting infectious disease is the first line of defense to minimize the damage from the spread of diseases, by detecting them at an early stage and stop its transmission to the community," she said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spray, a drug-free nasal spray designed to form a protective barrier on the nasal lining—offering a modern solution in the post-mask era. A Physical Barrier, Not a Medication Unlike traditional nasal sprays that rely on steroids or antihistamines, LUCA V-Defense forms a non-medicated barrier across the nasal mucosa, the body's first line of defense against airborne pathogens. Instead of using steroids, antihistamines, or vasoconstrictors, LUCA V-Defense relies on lambda carrageenan, a natural compound extracted from red algae, and antimicrobial lipids. These ingredients coat the nasal lining, helping to prevent viruses like SARS-CoV-2 and influenza from binding to mucosal cells. Recent studies have also shown that lambda carrageenan not only possesses antiviral properties but also exhibits anti-inflammatory and anti-allergic effects, helping to reduce allergic reactions in nasal tissues and inhibit histamine release, which may contribute to the prevention of allergic rhinitis. Using LUCA's proprietary lipid nanocoating technology, the nasal spray demonstrated 99.7% antiviral efficacy within one minute in an in vitro third-party COVID-19 lab study overseas. This suggests potential across a broad spectrum of respiratory viruses. Rapid Adoption and International Certifications LUCA AICELL reports that sales of LUCA V-Defense more than tripled in the most recent quarter, signaling increasing consumer interest in preventive nasal sprays. This demand is especially strong among parents and travelers, given that no vaccine currently exists for Mycoplasma pneumonia, a common threat to children. LUCA V-Defense is classified as a medical device, not a pharmaceutical. It holds: These credentials validate its safety for daily use and its alignment with international regulatory standards. Safer than Steroid and Decongestant Sprays Many popular nasal congestion sprays contain steroids or vasoconstrictors like methazoline, which can offer fast symptom relief but are linked to rebound congestion, mucosal thinning, and reduced efficacy with long-term use. LUCA V-Defense addresses these issues with a plant-based, non-pharmaceutical formulation that's free from steroids, antihistamines, and methazoline. It is gentle enough for children, pregnant women, and individuals who suffer from seasonal allergies or chronic rhinitis. Its ease of use, a simple mist inside each nostril, makes it ideal for travel, commutes, or high-exposure environments like offices, schools, or public transit. As the world transitions away from masks and into a new phase of pandemic management, personal preventive tools like LUCA V-Defense are gaining relevance. Whether navigating crowded airports, allergy season, or cold and flu outbreaks, this daily-use nasal spray offers a chemical-free alternative for respiratory defense. "The pandemic changed how we think about personal protection," said a LUCA AICELL spokesperson. "LUCA V-Defense was developed not just for short-term response, but for long-term respiratory wellness. We see it as a smart, science-backed addition to modern health routines."
Korea Herald
2 days ago
- Korea Herald
Infectious disease cases up 54.5% in South Korea
South Korea saw a 54.5 percent rise in non-COVID notifiable infectious disease cases in 2024 compared to the previous year, driven largely by a surge in respiratory illnesses among children, according to a new report from the Korea Disease Control and Prevention Agency on Thursday. The 2024 annual report on infectious disease, based on data from the newly launched integrated control information system, found that 168,586 cases of first to third-tier notifiable diseases — excluding COVID-19 and syphilis, which both had changes in their tiers — were reported last year, up from 109,087 in 2023. Pertussis, otherwise known as whooping cough, accounted for much of the increase, with cases jumping from just 292 in 2023 to 48,048, over a 164-fold increase, in 2024. Scarlet fever and chickenpox also surged, with 6,642 and 31,892 cases reported, respectively. Carbapenem-resistant Enterobacteriaceae, a dangerous antibiotic-resistant infection, reached 42,347 cases. Despite the overall increase in these illnesses, the total number of reported cases of all monitored infectious diseases plummeted by 97 percent from 2023, largely due to the reclassification of COVID-19 as a lower-tier disease. The number of deaths from notifiable diseases, excluding tuberculosis, rose 18.2 percent to 1,238 in 2024. CRE infections were the leading cause of death among these, with 838 fatalities. KDCA Commissioner Jee Young-mee emphasized the importance of early reporting by medical institutions. "Reporting infectious disease is the first line of defense to minimize the damage from the spread of diseases, by detecting them at an early stage and stop its transmission to the community," she said.
Korea Herald
19-06-2025
- Korea Herald
Kennedy's panel to discuss measles shot
WASHINGTON (Reuters) — US vaccine advisers will discuss recommendations for flu vaccines containing the preservative thimerosal and a combination measles shot for children this month, putting topics of concern to Health Secretary Robert F. Kennedy Jr. high on the public health agenda. Kennedy, who has a long history of sowing doubt over the safety of vaccines, contrary to scientific evidence, wrote a book in 2014 claiming that thimerosal, a mercury-based preservative, causes brain damage. He has also prominently promoted the idea that vaccines that combine shots against measles, mumps and rubella, as well as varicella are linked to autism. Repeated scientific studies have disproved both assertions. Since taking the role of top US health official under the Trump administration, Kennedy is changing vaccine policies for the American public. He recently asked for a review of all data including for the measles shot, by far the best way to prevent infection with the highly contagious and sometimes deadly virus. The panel, known as the Advisory Committee on Immunization Practice, is due to meet on June 25 and 26. It will vote on the safety of flu shots and discuss proposed recommendations for use of the combined MMRV vaccine for children under 5 years of age, according to a draft agenda on Centers for Disease Control and Prevention's website on Wednesday. While the seasonal flu shot was expected to be on the meeting agenda, neither the topic of thimerosal nor the MMRV vaccine was anticipated. The meeting agenda did not specify who will be presenting data on either subject. The Department of Health and Human Services declined to comment on the record on why topics were added to the agenda or who would be making presentations. "It's not clear why thimerosal is up for a vote or discussion, unless the goal is to repeat an old anti-vaccine trope that the data does not support — that thimerosal in vaccines is harmful — and use it as a messaging point," said Dorit Reiss, a vaccine law expert at UC Law San Francisco. The committee will also vote on use of RSV vaccines, but not the next COVID-19 boosters, as originally expected, according to the agenda. Other expected votes were also removed. "The reason for the discussion of MMRV is also unclear, and the fact that the presenter is (yet to be named) raises questions," Reiss said. "Also interesting is what is not on the schedule. Why is there no vote on COVID-19 vaccines with the fall season coming up, and questions about who should get boosters?" The agenda was posted after Kennedy abruptly fired all 17 ACIP members and named eight new advisers, including several who have advocated against vaccines. "It's disappointing to see scarce public health resources used to rehash settled science," said recently fired ACIP member Noel Brewer. "Substantial research across decades has shown the safety of thimerosal as a preservative in vaccination." Thimerosal has long been used in the United States in vials of medicines and vaccines that contain more than one dose, according to the CDC. Aside from minor reactions such as redness and swelling at the injection site, there is no evidence of harm caused by the low doses of thimerosal in vaccines, the agency says. Combination vaccines to prevent infection with measles, mumps and rubella viruses are marketed in the United States by Merck and GSK. Merck also sells the ProQuad shot that includes protection against those three viruses and varicella. For children under age 4 years, the CDC currently recommends that most receive a first dose of an MMR vaccine and a separate varicella shot. For the second dose, and for children over 4, the CDC says the MMRV vaccine is generally preferred over separate shots.
